Pepfast Enters Hong Kong Market Through Homecare Partnership

Pepfast, our rapid and non‑invasive reflux test, has been commercialized in Hong Kong through a partnership with The HomeCare Medical Limited.

The product received NMPA registration in May 2025 and was launched immediately. By July 2025, it had already entered the Hong Kong market through this collaboration.

Our first discussion with the partner dates back to 2023. After learning about our pepsin detection technology, the homecare provider expressed strong interest and waited specifically for the launch of Pepfast—a streamlined version designed for broader clinical accessibility.

Pepfast enabling rapid, on-site reflux screening without the need for laboratory equipment or centrifugation. It delivers objective results in just 15 minutes from a single saliva sample.

“We are pleased to bring Pepfast to Hong Kong through this partnership,” said a Maxhealth representative. “Designed as a simple yet objective screening tool, it aligns well with the growing demand for community‑based diagnostic solutions. We look forward to expanding access to convenient reflux testing across more regions.”